POPULARITY
9 episodes with mpdl3280a
6 episodes with mpdl3280a
2 episodes with mpdl3280a
2 episodes with mpdl3280a
Dr Hoffman-Censits talks to ecancertv at ASCO GU 2016 about IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUc). Dr Hoffman-Censits discusses the poor overall response rate and survival of mUC patients who progress after platinum-based chemotherapy. The trial demonstrated significantly improved overall response rate when compared to historic controls. Responses were found to be durable and associated with higher PD-L1 IC expression while poor prognostic factors did not preclude response. Atezolizumab was well tolerated, and a randomized phase III study vs cetuximab is ongoing.
Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.
Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.
Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first line chemotherapy or targeted therapy vs. sequential treatment.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Ben Solomon, Leora Horn, & Jack West consider whether immunotherapy might prove to be more problematic when given to a broader population of older and frail patients with advanced lung cancer.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Drs. Leora Horn, Ben Solomon, & Jack West review the potential rationale and possible limitations of combining different immuntherapy strategies with one another.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether the data suggest that the better tested PD1 and PD-L1 inhibitors have differences in activity or tolerability or are essentially interchangeable.
Prof Emens talks to ecancertv at AACR 2015 about how an investigational immunotherapy, MPDL3280A, was safe, tolerable, and showed early signs of durable clinical activity in patients with metastatic triple-negative breast cancer.
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
Today in FirstWord:
Today in FirstWord:
Prof Thomas Powles (Barts Health, London, UK) discusses the use of the drug MPDL3280A to inhibit the protein PD-L1 in patients with metatastatic urothelial bladder cancer.
Prof Jean-Charles Soria talks with ecancer at ECC 2013 about the most up-to-date data from 85 patients with non-small cell lung cancer in a large, phase I clinical trial of an experimental drug called MPDL3280A. New results from a trial of an antibody that helps the immune system to recognise and attack cancer cells have shown particularly encouraging responses in patients who are smokers or former smokers.
Prof Cora Sternberg, scientific co-chair of ECC 2013, comments on the findings of Prof Jean-Charles Soria and his team on the most up-to-date data from 85 patients with non-small cell lung cancer in a large, phase I clinical trial of an experimental drug called MPDL3280A.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, covers the provocative results of the novel immune checkpoint PD-L1 inhibitor MPDL3280A in advanced NSCLC.
© 2020-2025 Ivy Podcast Discovery LLC
